Asset Details
Do you wish to reserve the book?
Prediction of outcome of early ER+ breast cancer is improved using a biomarker panel, which includes Ki-67 and p53
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Prediction of outcome of early ER+ breast cancer is improved using a biomarker panel, which includes Ki-67 and p53
Do you wish to request the book?
Prediction of outcome of early ER+ breast cancer is improved using a biomarker panel, which includes Ki-67 and p53
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Prediction of outcome of early ER+ breast cancer is improved using a biomarker panel, which includes Ki-67 and p53
2011
Overview
Background:
The aim of this study is to determine whether immunohistochemical (IHC) assessment of Ki67 and p53 improves prognostication of oestrogen receptor-positive (ER+) breast cancer after breast-conserving therapy (BCT). In all, 498 patients with invasive breast cancer from a randomised trial of BCT with or without tumour bed radiation boost were assessed using IHC.
Methods:
The ER+ tumours were classified as ‘luminal A’ (LA): ER+ and/or PR+, Ki-67 low, p53−, HER2− or ‘luminal B’ (LB): ER+ and/or PR+and/or Ki-67 high and/or p53+ and/or HER2+. Kaplan–Meier and Cox proportional hazards methodology were used to ascertain relationships to ispilateral breast tumour recurrence (IBTR), locoregional recurrence (LRR), distant metastasis-free survival (DMFS) and breast cancer-specific survival (BCSS).
Results:
In all, 73 patients previously LA were re-classified as LB: a greater than four-fold increase (4.6–19.3%) compared with ER, PR, HER2 alone. In multivariate analysis, the LB signature independently predicted LRR (hazard ratio (HR) 3.612, 95% CI 1.555–8.340,
P
=0.003), DMFS (HR 3.023, 95% CI 1.501–6.087,
P
=0.002) and BCSS (HR 3.617, 95% CI 1.629–8.031,
P
=0.002) but not IBTR.
Conclusion:
The prognostic evaluation of ER+ breast cancer is improved using a marker panel, which includes Ki-67 and p53. This may help better define a group of poor prognosis ER+ patients with a greater probability of failure with endocrine therapy.
Publisher
Nature Publishing Group UK,Nature Publishing Group
Subject
/ Biological and medical sciences
/ Biomarkers, Tumor - analysis
/ Biomarkers, Tumor - metabolism
/ Biomarkers, Tumor - physiology
/ Biomedical and Life Sciences
/ Breast Neoplasms - diagnosis
/ Breast Neoplasms - metabolism
/ Breast Neoplasms - pathology
/ Female
/ Gynecology. Andrology. Obstetrics
/ Humans
/ Oncology
/ Randomized Controlled Trials as Topic
/ Receptors, Estrogen - metabolism
/ Tumor Suppressor Protein p53 - analysis
/ Tumor Suppressor Protein p53 - metabolism
/ Tumor Suppressor Protein p53 - physiology
/ Tumors
